Starling Oncology (STLNW) Depreciation & Amortization - Total (2021 - 2026)

Starling Oncology (STLNW) has reported Depreciation & Amortization - Total for 6 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Depreciation & Amortization - Total rose 8.72% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $3.9 million (up 4.45% YoY), and the FY2025 full-year result was $4.0 million, up 24.15% from the prior year.
• Depreciation & Amortization - Total grew to $1.1 million in Q2 2026 per STLNW's latest filing, from $901000.0 in the prior quarter.
• Across five years, Depreciation & Amortization - Total topped out at $1.1 million in Q2 2026 and bottomed at $314000.0 in Q1 2022.
• Historically, Depreciation & Amortization - Total has averaged $753888.9 across 5 years, with a median of $804000.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization - Total soared 132.57% in 2023, then retreated 12.47% in 2024.
• Over 5 years, Depreciation & Amortization - Total stood at $460000.0 in 2022, then soared by 75.65% to $808000.0 in 2023, then grew by 15.47% to $933000.0 in 2024, then dropped by 1.93% to $915000.0 in 2025, then increased by 22.62% to $1.1 million in 2026.
• According to Business Quant data, Depreciation & Amortization - Total over the past three periods registered $1.1 million, $901000.0, and $915000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.